Gregory A Grabowski

US Patent:

20030059420, Mar 27, 2003

Filed:

Feb 2, 2001

Appl. No.:

09/775517

Inventors:

Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US

International Classification:

A61K038/46
A61K038/16

US Classification:

424/094600, 514/008000

Abstract:

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

US Patent:

20040223960, Nov 11, 2004

Filed:

Feb 11, 2004

Appl. No.:

10/776797

Inventors:

Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US

International Classification:

A61K038/46

US Classification:

424/094600

Abstract:

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

US Patent:

20070264249, Nov 15, 2007

Filed:

Jan 12, 2007

Appl. No.:

11/653147

Inventors:

Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US

International Classification:

A61K 38/46
A61P 43/00

US Classification:

424094600

Abstract:

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

US Patent:

20090297496, Dec 3, 2009

Filed:

Aug 31, 2006

Appl. No.:

12/065975

Inventors:

Gregory A. Grabowski - Cincinnati OH, US

Assignee:

Childrens Hospital Medical Center - Cincinnati OH

International Classification:

A61K 38/46
A61K 38/16
A61K 38/02
C12P 21/00
C12N 15/63
A61P 1/16

US Classification:

424 946, 514 12, 514 2, 435 691, 435455

Abstract:

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,

US Patent:

20100239558, Sep 23, 2010

Filed:

Jan 6, 2010

Appl. No.:

12/683265

Inventors:

Gregory A. Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US

International Classification:

A61K 38/46
A61P 9/10
A61P 9/00
A61K 31/7088
C12N 15/09

US Classification:

424 946, 514 44 R, 435455

Abstract:

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

US Patent:

20190125842, May 2, 2019

Filed:

Sep 26, 2018

Appl. No.:

16/142136

Inventors:

- Cincinnati OH, US
Gregory A. Grabowski - Wheat Ridge CO, US

International Classification:

A61K 38/46
A61K 9/00
A61K 45/06

Abstract:

The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,